. Author manuscript; available in PMC: 2015 Oct 24.

Published in final edited form as: Int J Cancer. 2014 May 15;136(1):172–181. doi: 10.1002/ijc.28953

Table 1.

LTBP2, OPN and AFP performance when comparing various sample groups in the three case-control studies.

Case-control study	Group 1 (Marker)	Group 2 (Marker)	AUROC	95% CI	Cutoff (ng/mL)	Sensitivity (95% CI)	Specificity (95% CI)
Thailand	CLD (AFP)	HCC (AFP)	0.57	0.31-0.84	20 ng/mL	85%; CI: 72%-93%	100%; CI: 79%-100%
Thailand	CLD (LTBP2 with AFP<20 ng/mL)	HCC (LTBP2 with AFP<20 ng/mL)	0.98	0.93-1.00	27 ng/mL	100%; CI: 57%-100%	94%; CI: 70%-99%
The Gambia	CLD (AFP)	HCC (AFP)	0.59	0.39-0.79	20 ng/mL	76%; CI: 61%-87%	86%; CI: 72%-94%
The Gambia	CLD (LTBP2+OPN with AFP<20 ng/mL)	HCC (LTBP2+OPN with AFP<20 ng/mL)	0.85	0.74-0.96	27&237 ng/mL	92%; CI: 62%-99%	70%; CI: 53%-83%
France	CLD (AFP)	HCC (AFP)	0.57	0.45-0.69	20 ng/mL	49%; CI: 37%-62%	86%; CI: 74%-94%
	CLD (LTBP2 with AFP<20 ng/mL)	HCC (LTBP2 with AFP<20 ng/mL)	0.57	0.45-0.70	27 ng/mL	69%; CI: 54%-81%	36%; CI: 20%-54%
	CLD (OPN with AFP<20 ng/mL)	HCC (OPN with AFP<20 ng/mL)	0.70	0.59-0.83	91 ng/mL	83%; CI: 69%-93%	56%; CI: 38%-72%

Sensitivity and specificity of LTBP2, OPN and AFP are assessed for corresponding cutoffs according to sample groups analysed. AUROC = area under the receiver operating curve, CLD = chronic liver disease patients, HCC = hepatocellular carcinoma patients.